新的口服抗生素(Tebipenem HBR)被证明是治疗住院病人严重尿道感染的有效和安全的,有可能成为第一个口服卡巴彭。 A new oral antibiotic, tebipenem HBr, proved effective and safe for treating severe urinary tract infections in hospitalized patients, potentially becoming the first oral carbapenem.

2025年在IDWeek举行的第3阶段试验显示,口服抗生素调查性口服抗生素Tebipenem HBR对治疗住院病人的复杂尿道感染,包括白喉关节炎,是有效和安全的。 A Phase 3 trial presented at IDWeek 2025 showed tebipenem HBr, an investigational oral antibiotic, was effective and safe for treating complicated urinary tract infections, including pyelonephritis, in hospitalized patients. 该药物在总体成功率方面与标准的四类治疗方法相匹配,在抗药性感染患者中也显示出类似的结果。 The drug matched the standard IV treatment in overall success rate and showed similar results in patients with drug-resistant infections. 通过FDA快速跟踪和QIDP的指定, 它可能成为第一个口服的卡巴胺抗生素. With FDA Fast Track and QIDP designations, it could become the first oral carbapenem antibiotic. Spero计划到2025年底向美国监管机构提交数据。 Spero plans to submit data to U.S. regulators by the end of 2025.